MarketCap
Facebook
X
Telegram
BioNano Genomics Net Income | BNGO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income BioNano Genomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -26.4 M | -112 M | -232 M | -133 M | -72.4 M | -41.1 M | -29.8 M | -18.5 M | -23.4 M | -18.8 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.5 M | -232 M | -70.8 M |
Quarterly Net Income BioNano Genomics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.1 M | -8.3 M | - | -8.5 M | -6.86 M | -3.1 M | - | -44.2 M | -16.2 M | -31.4 M | - | -113 M | -38.9 M | -37.1 M | - | -31.8 M | -32.2 M | -30 M | - | -20.8 M | -18.8 M | -9.95 M | - | -10.8 M | -8.07 M | -10.5 M | -7.9 M | -6.4 M | -6.4 M | -7.9 M | -6.41 M | -4.93 M | -3.31 M | -3.85 M | 5.92 M | -23.4 M | 6.67 M | 5.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.67 M | -113 M | -16.7 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Biomerica
BMRA
|
-3.78 M | $ 1.73 | 2.98 % | $ 5.04 M | USA |
 |
Myriad Genetics
MYGN
|
-366 M | $ 5.93 | 1.87 % | $ 549 M | USA |
 |
Pacific Biosciences of California
PACB
|
-546 M | $ 2.27 | 7.58 % | $ 681 M | USA |
 |
Neuronetics
STIM
|
-39 M | $ 2.24 | 5.92 % | $ 148 M | USA |
 |
Agilent Technologies
A
|
1.3 B | $ 175.71 | 1.56 % | $ 49.9 B | USA |
 |
Charles River Laboratories International
CRL
|
-144 M | $ 354.37 | 2.67 % | $ 17.6 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
-11.5 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
-99.8 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
266 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-55.3 M | $ 11.95 | 1.1 % | $ 126 M |  China |
 |
Renalytix AI plc
RNLX
|
-33.5 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Bioventus
BVS
|
22.7 M | $ 14.71 | -1.67 % | $ 980 M | USA |
 |
Psychemedics Corporation
PMD
|
-1.86 M | - | -1.84 % | $ 15.3 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
897 M | $ 26.77 | -0.48 % | $ 25.4 B |  Niderland |
 |
Meridian Bioscience
VIVO
|
42.5 M | - | - | $ 1.49 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-50 M | - | -61.36 % | $ 2.46 M | USA |
 |
T2 Biosystems
TTOO
|
-50.1 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Celcuity
CELC
|
-177 M | $ 66.71 | 2.26 % | $ 3.12 B | USA |
 |
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
-46.9 M | $ 0.56 | 3.12 % | $ 745 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
992 M | $ 241.85 | 0.02 % | $ 26.8 B | USA |
 |
Danaher Corporation
DHR
|
3.61 B | $ 232.05 | 0.7 % | $ 165 B | USA |
 |
DexCom
DXCM
|
836 M | $ 77.69 | -0.33 % | $ 30.3 B | USA |
 |
Castle Biosciences
CSTL
|
-24.2 M | $ 33.16 | 0.24 % | $ 961 M | USA |
 |
Fulgent Genetics
FLGT
|
-60.5 M | $ 20.41 | 1.54 % | $ 628 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-416 M | $ 174.47 | 3.19 % | $ 21.9 B | USA |
 |
Quotient Limited
QTNT
|
-125 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
IDEXX Laboratories
IDXX
|
1.06 B | $ 568.76 | 1.5 % | $ 45.7 B | USA |
 |
Illumina
ILMN
|
850 M | $ 271.02 | 0.59 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
1.36 B | $ 275.32 | -1.44 % | $ 47.3 B | USA |
 |
Lantheus Holdings
LNTH
|
234 M | $ 100.0 | 0.2 % | $ 6.75 B | USA |
 |
CareDx, Inc
CDNA
|
-21.4 M | $ 68.8 | -0.6 % | $ 3.67 B | USA |
 |
Medpace Holdings
MEDP
|
451 M | $ 675.22 | 0.9 % | $ 19.5 B | USA |
 |
Mettler-Toledo International
MTD
|
869 M | $ 1 667.03 | -0.07 % | $ 34.4 B | Schweiz |
 |
ENDRA Life Sciences
NDRA
|
-7.03 M | $ 4.86 | 1.25 % | $ 3.82 M | USA |
 |
Neogen Corporation
NEOG
|
-7.9 M | $ 12.31 | 0.98 % | $ 2.68 B | USA |
 |
National Research Corporation
NRC
|
11.6 M | $ 22.33 | 1.82 % | $ 500 M | USA |
 |
Natera
NTRA
|
-208 M | $ 403.93 | 0.27 % | $ 55.2 B | USA |
 |
OPKO Health
OPK
|
-226 B | $ 1.66 | 1.53 % | $ 1.25 B | USA |
 |
Precipio
PRPO
|
-363 K | $ 19.23 | -3.9 % | $ 30.9 M | USA |
 |
RadNet
RDNT
|
-18.6 M | $ 70.49 | 0.21 % | $ 5.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
229 M | $ 184.42 | -0.46 % | $ 14.5 B |  Irlanda |
 |
Senseonics Holdings
SENS
|
-69.1 M | $ 7.6 | 1.2 % | $ 317 M | USA |